Overview


According to FutureWise analysis the market for atopic dermatitis in 2023 is US$ 7.05 billion, and is expected to reach US$ 22.05 billion by 2031 at a CAGR of 15.32%.

An inflammatory skin condition called atopic dermatitis varies in intensity from patient to patient. It typically starts in childhood and is mostly limited to the flexural surfaces of the body. It is far more frequently referred to as eczema and is extremely common. It is a chronic condition with symptoms like itchiness, skin redness, cracking, weeping, etc. Seasonal allergies, cold temperatures, and low humidity are typical causes, and the severity of the sickness will define the appropriate course of therapy. Atopic dermatitis patients may experience rashes on any part of their bodies that, if touched, can ooze, drip fluid, and bleed, leaving the skin susceptible to infection. Repeated scratching may cause the skin to thicken and harden (lichenify), and the skin can become dry and discolored.

There is currently no known test for Atopic dermatitis, and neither a symptom nor a trait can be used to pinpoint the condition. Each patient has a contrasting set of symptoms and rash characteristics. The patient's medical history and physical examination are used to diagnose atopic dermatitis. A skin biopsy may be performed in circumstances where a histological diagnosis of dermatitis is questionable. The diagnosis is made primarily on the appearance of the signs and symptoms; however, contact dermatitis, psoriasis, and seborrheic dermatitis must first be ruled out. Additionally, procedures and safeguards can be costly in terms of time, effort, and money. Despite the lack of a cure, some therapies can reduce the symptoms.

FutureWise Market Research has published a report that provides an insightful analysis of atopic dermatitis market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the atopic dermatitis market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Abbvie Inc.
  • Allergan PLC
  • Bausch Health Companies Inc.
  • Encore Dermatology Inc.
  • GlaxoSmithKline PLC
  • Nestle SA
  • Novartis International AG
  • Pfizer Inc.
  • Regenron Pharmaceutical Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Atopic Dermatitis Market:

June 2022- Sanofi got USFDA approval for Dupixent (dupilumab) for use in children with moderate-to-severe atopic dermatitis who are 6 months to 5 years old and whose condition cannot be well controlled by topical prescription medications or in situations where those therapies are not recommended.

An individual comes into contact with millions of chemical compounds during their lifetime. Recently, there has been an upsurge in chemical allergy exposure from various sources, notably in developed countries. Some of these enter our environment as industrial dust, tobacco smoke, herbicides, fertilizers, and insecticides. The majority of personal hygiene items, cosmetics, processed foods, and prescriptions also contain preservatives, pigments, fragrances, surfactants, chelating agents, and taste enhancers. Dental implants, prosthetics, jewelry, and amalgam fillings all potentially release heavy metals. Increased exposure to chemical allergens, which promote the development of allergens, is thought to be the cause of the significant increase in AD and allergy incidence seen in developed nations over the past several years. The atopic dermatitis market is anticipated to expand due to a rise in skin allergens. The potential of the industry is also expected to grow due to the growing number of initiatives from various governments. The function of medical institutions in AD therapy has become more crucial in terms of educating people about AD and its treatment. Moreover, Eczema treatments are currently being developed at a rate that has never before been achieved, offering cutting-edge therapeutic choices with little morbidity. This includes treatments, including surgical procedures and prescription drugs like corticosteroids, antibiotics, emollients, and biological therapy. According to recent reports, the chronic nature of AD is leading to an increase in the use of complementary and alternative medicines (such as oriental herbal therapies). However, Atopic dermatitis market demand is constrained by growing challenges and unfavorable side effects that some patients experience after undergoing treatment. In addition, if taken for a prolonged period of time, oral drugs may have substantial side effects. Economic policy changes and the demand for more skilled staff in hospitals and clinics substantially impact the market for atopic dermatitis therapies. For market operators, the shortage of necessary equipment in rural areas remains a challenge. A second factor contributing to this industry's slow growth is the high cost of treatment due to modern technology.

By Drug Class

  • Corticosteroids
  • Emollients/Moisturizers
  • IL-4 and PDE4 Inhibitors
  • Calcineurin Inhibitors
  • Antibiotics
  • Other Drug Classes

By Route of Administration

  • Topical
  • Oral
  • Injectable

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. The availability of a well-established R&D infrastructure and favorable reimbursement rules are two major factors contributing to the region's dominance. In addition, the regulatory and reimbursement environment is constantly changing to keep up with the rapid advancement of research in this field. Additionally, the rising incidence of atopic dermatitis, strong treatment awareness among patients nationwide, a well-established healthcare system, and early uptake of innovative drugs all contribute to the market's expansion in the region. Moreover, based on drug class; topical Jak inhibitor holds the highest share in the market.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Atopic Dermatitis Market By Drug Class, By Route of Administration and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Atopic Dermatitis Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Atopic Dermatitis Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Atopic Dermatitis Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Atopic Dermatitis Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Corticosteroids
        2. Emollients/Moisturizers
        3. IL-4 and PDE4 Inhibitors
        4. Calcineurin Inhibitors
        5. Antibiotics
        6. Other Drug Classes

  • 8.   Atopic Dermatitis Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Topical
        2. Oral
        3. Injectable

  • 9.   North America Atopic Dermatitis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Atopic Dermatitis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Atopic Dermatitis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Atopic Dermatitis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Abbvie Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Allergan PLC
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bausch Health Companies Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Encore Dermatology Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithKline PLC
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Nestle SA
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Novartis International AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Pfizer Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Regenron Pharmaceutical Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients